Treatment with EGFR inhibitor, such as cetuximab, combined with the anti-IGF-IR antibody, has been shown to reduce proliferation and induced apoptosis in cSCC cells in vitro, showing that this approach could be useful for the treatment of cSCC (92). The gene discussed is EGFR; the disease is skin squamous cell carcinoma.